Espinach RM

Language: Spanish
References: 28
Page: 87-92
PDF size: 231.49 Kb.

Text Extraction

No abstract.

REFERENCES

1. Jaffe JA Liftman C Glickman JD. Frequency of elevated serum aluminum levels in adult dialysis patients. Am J Kidney Dis. 2005;46(2):316-319.

2. Humpfner A Hummel S Schultz W. Diagnosis and therapeutic approaches to aluminum overload in dialyzed patients-- representative study questionnaire in West German dialysis units in 1989-1990. Nephrol Dial Transplant. 1993;8:S51-S54.

3. Salusky IB. A new era in phosphate binder therapy: What are the options? Kidney Int. 2006;105:S10-S15.

4. Fernández-Martin JL Canteros A Serrano M Gonzalez-Carcedo A Díaz-Corte C Cannata, JB. Prevention of aluminum exposure through dialysis fluids. Analysis of changes in the last 8 years. Nephrol Dial Transplant. 1998;13: S78–S81.

5. Savory J Berlin A Courtoux C Yeoman B Wills M. Summary report of an international workshop on “The role of biological monitoring in the prevention of aluminum toxicity in man: Aluminum analysis in biological fluids.” Ann Clin Lab. 1989;13: 444-451.

6. Slatopolsky E. The interaction of parathyroid hormone and aluminum in renal osteodystrophy. Kidney Int. 1987;31(3):842- 854.

7. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S108- S122.

8. Koiwa F Sato Y. Chemistry and history of phosphate binder. Clin Calcium. 2009;19: 198-204.

9. Jaffe JA Liftman C Glickman JD. Frequency of elevated serum aluminum levels in adult dialysis patients. Am J Kidney Dis. 2005;46 (2):316-319.

10. Kan WC Chien CC Wu CC Su SB Hwang JC Wang HY. Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients. Nephrol Dial Transplant. 2010;25(5):1604- 1608.

11. Berlyne GM Pest D Ben-Ari J et al. Hyperaluminaemia from aluminum resins in renal failure. Lancet. 1970;296(7671):494– 496.

12. Sherrard DJ. Letter: the myth of aluminum toxicity. N Engl J Med. 1974;290:750.

13. Wei-Chih K Chih-Chiang Ch Yi-Hua L Jyh- Chang H Shih-Bin S Hsien-Yi W. Aluminum Overload: An Easily - Ignored Problem in Dialysis Patients with Hyperparathyroidism. ISBN: 978-953-51-0478-0, InTech, Available from: http://www.intechopen.com/books/hyperparat hyroidism/aluminum-overload-an-easilyignored- problem-in-dialysis-patients-withhyperparathyroidism

14. Alfrey AC. Aluminum toxicity in patients with chronic renal failure. Ther Drug Monit. 1993;15(6):593-597.

15. Alfrey AC LeGendre GR Kaehny WD. The dialysis encephalopathy syndrome: Possible aluminum intoxication. N Engl J Med. 1976;294(4):184-188.

16. House RA. Factors affecting plasma aluminum concentrations in nonexposed workers. J Occup Med. 1992;34:1013-1017.

17. U.S. department of Health and Human Services. Public Health Service Agency for Toxic Substances and Disease Registry. Toxicological profile for aluminum. September 2008.

18. Cannata JB Fernández-Soto I Fernández- Menéndez MJ et al. Role of iron metabolism in absorption and cellular uptake of aluminum. Kidney Int.1991;39(4):799–803.

19. Losekann A Ureña P Khiraoui F et al. Aluminium intoxication in the rat induces partial resistan e to the effect of recombinant human erythropoietin. Nephrol Dial Transplant. 1990;5(4):258–263.

20. Drüeke TB. Resistance to recombinant human erythropoietin in hemodialysis patients. Am J Nephrol. 1990;10(2):S34–S39.

21. Malluche H. Aluminum and bone disease in chronic renal failure. Nephrol Dial Trasplant. 2002;17(2):S21-S24.

22. Norris KC Crooks PW Nebeker HG et al. (1985). Clinical and laboratory features of aluminum-related bone disease: Differences between sporadic and “epidemic” forms of the syndrome. Am J Kidney Dis. 1985;6:342- 347.

23. Diaz-Corte C Fernandez Martin JL. Effect of aluminium load on parathyroid hormone synthesis. Nephrol Dial Trasplant. 2001;16: 742-745.

24. Andreoli SP Bergstein JM Sherrard DJ. Aluminum intoxication from aluminumcontaining phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med. 1984;310:1079-1084.

25. Brem AS DiMario C Levy DL. Perceived Aluminum-Related Disease in a Dialysis Population A Report From the End-Stage Renal Disease Network 28. Arch Intern Med. 1989;149:2541-2544.

26. McCauley J Sorkin MI. Exacerbation of aluminum encephalopathy after treatment with desferrioxamine. Nephrol Dial Transplant. 1989;4(2):110-114.

27. Bene C Manzler A Bene D Kranias G. Irreversible ocular toxicity from single “challenge” dose of deferoxamine. Clin Nephrol. 1989;31(1):45-48.

28. Kan WC Chien CC Wu CC Su SB Hwang JC Wang HY. Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients. Nephrol Dial Transplant. 2010;25(5):1604- 1608.